We are live on
!
Find out more
DekaBank Deutsche Girozentrale Portfolio holdings
AUM
$59.2B
1-Year Est. Return
26.02%
This Fund
S&P 500
This Quarter
Est. Return
+8.43%
1 Year Est. Return
+26.02%
3 Year Est. Return
+92.08%
5 Year Est. Return
+125.09%
10 Year Est. Return
+457.34%
AUM
$34.3B
AUM Growth
+$4.15B
(+14%)
Cap. Flow
+$1.92B
Cap. Flow
% of AUM
5.6%
Top 10 Holdings %
Top 10 Hldgs %
23.44%
Holding
1,439
New
97
Increased
478
Reduced
443
Closed
54
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Stellantis
STLA
|
+$200M |
| 2 |
Amazon
AMZN
|
+$126M |
| 3 |
Deutsche Bank
DB
|
+$109M |
| 4 |
Intuitive Surgical
ISRG
|
+$92.2M |
| 5 |
Wells Fargo
WFC
|
+$83.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$126M |
| 2 |
Abbott
ABT
|
+$79.1M |
| 3 |
VF Corp
VFC
|
+$49M |
| 4 |
JPMorgan Chase
JPM
|
+$48.5M |
| 5 |
BioNTech
BNTX
|
+$46.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.97% |
| 2 | Healthcare | 15.46% |
| 3 | Financials | 11.88% |
| 4 | Communication Services | 9.65% |
| 5 | Consumer Discretionary | 9.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ENDP
1126
DELISTED
Endo International plc
ENDP
| $352K | ﹤0.01% |
76,600
| – | – |
|
1127
Nurix Therapeutics
NRIX
$2.69B
| $344K | ﹤0.01% |
12,400
| – | – |
|
1128
Melco Resorts & Entertainment
MLCO
$2.12B
| $341K | ﹤0.01% |
21,140
+761
| +4% | +$13.8K |
|
1129
DoorDash
DASH
$90.9B
| $336K | ﹤0.01% |
+1,825
| New | +$268K |
|
1130
Globant
GLOB
$1.66B
| $334K | ﹤0.01% |
1,500
-510
| -25% | -$112K |
|
1131
Pliant Therapeutics
PLRX
$64.4M
| $333K | ﹤0.01% |
12,000
| – | – |
|
|
ZGNX
1132
DELISTED
Zogenix, Inc.
ZGNX
| $329K | ﹤0.01% |
18,600
| – | – |
|
1133
Imperial Oil
IMO
$62.3B
| $324K | ﹤0.01% |
10,844
+777
| +8% | +$23.4K |
|
1134
Schneider National
SNDR
$6.18B
| $322K | ﹤0.01% |
14,909
| – | – |
|
1135
Arcutis Biotherapeutics
ARQT
$3.26B
| $320K | ﹤0.01% |
12,400
| – | – |
|
|
RNAM
1136
DELISTED
Avidity Biosciences
RNAM
| $320K | ﹤0.01% |
14,000
| – | – |
|
1137
Nkarta
NKTX
$176M
| $312K | ﹤0.01% |
10,500
| – | – |
|
1138
Ocular Therapeutix
OCUL
$2.03B
| $312K | ﹤0.01% |
22,900
| – | – |
|
1139
Bausch Health
BHC
$2.37B
| $309K | ﹤0.01% |
10,716
+513
| +5% | +$15.5K |
|
1140
Immunovant
IMVT
$8.24B
| $309K | ﹤0.01% |
28,600
| – | – |
|
|
AKRO
1141
DELISTED
Akero Therapeutics
AKRO
| $305K | ﹤0.01% |
12,000
| – | – |
|
1142
CAE Inc. Common Shares
CAE
$8.64B
| $304K | ﹤0.01% |
10,024
+860
| +9% | +$26.3K |
|
1143
Amphastar Pharmaceuticals
AMPH
$896M
| $299K | ﹤0.01% |
14,900
| – | – |
|
|
AXON
1144
Axon Enterprise
AXON
$48.4B
| $297K | ﹤0.01% |
1,654
+670
| +68% | +$98.6K |
|
1145
Service Corp International
SCI
$11.4B
| $295K | ﹤0.01% |
5,526
+4,684
| +556% | +$249K |
|
1146
Teva Pharmaceuticals
TEVA
$42.1B
| $295K | ﹤0.01% |
29,365
+4,665
| +19% | +$49.4K |
|
1147
Precigen
PGEN
$2.51B
| $294K | ﹤0.01% |
46,500
| – | – |
|
1148
Corsair Gaming
CRSR
$1.48B
| $293K | ﹤0.01% |
9,000
+1,000
| +13% | +$32.9K |
|
1149
Dolby
DLB
$5.82B
| $293K | ﹤0.01% |
2,956
+468
| +19% | +$46.2K |
|
1150
Icon
ICLR
$12.8B
| $291K | ﹤0.01% |
1,357
-22,000
| -94% | -$4.75M |
|
Similar funds
QCM
NAMI
DekaBank Deutsche Girozentrale's Q2 2021 Portfolio in Review
As of Q2 2021, DekaBank Deutsche Girozentrale held 1,439 positions worth $34.3B, up 14% from $30.1B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
DekaBank Deutsche Girozentrale deployed $1.92B of net new capital in Q2 2021, opening 97 new positions and adding to 478 existing holdings. Its largest new stake was Stellantis: 10,647,151 shares worth $207M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 25% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Broadcom, an estimated $126M trimmed.
- DekaBank Deutsche Girozentrale's largest Q2 2021 buy was Stellantis: 10,647,151 shares worth $207M.
- DekaBank Deutsche Girozentrale added most to Amazon in Q2 2021, an estimated $126M increase.
- DekaBank Deutsche Girozentrale's biggest Q2 2021 reduction was Broadcom, cutting an estimated $126M.
- DekaBank Deutsche Girozentrale fully exited CureVac in Q2 2021, selling an estimated $6.93M.
- DekaBank Deutsche Girozentrale's ten largest holdings make up 23% of its $34.3B portfolio in Q2 2021.
- DekaBank Deutsche Girozentrale opened 97 new positions and closed 54 in Q2 2021.
- DekaBank Deutsche Girozentrale's portfolio value rose 14% quarter-over-quarter to $34.3B.
Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2021, filed 5 Aug 2021.